Back to search results

Understanding How MK-2828 Interacts with Other Medications

This study is for healthy adults aged 24 to 60 years old. Researchers want to understand how the drug MK-2828 interacts with other common medications, itraconazole and midazolam. Specifically, they will measure the levels of MK-2828 in your body when taken with itraconazole, and the levels of midazolam in your body when taken with MK-2828. This helps them learn if taking these medications together changes how much of each drug is in your system. You must be in good health to participate, and certain medical conditions like a history of cancer or significant organ problems would prevent you from joining. The study plans to enroll 28 participants.

Study design
This is an interventional study involving 28 healthy participants. It aims to understand drug interactions by measuring drug levels in the body.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Drug levels will be measured up to approximately 288 hours (about 12 days) after the last dose of MK-2828, and up to approximately 24 hours after the last dose of midazolam.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07435194

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

Active, Not Recruiting
PHASE1Ages 24–60InterventionalBasic science
Merck Sharp & Dohme LLC
~28 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:MK-2828ItraconazoleMidazolam

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part 1 (Itraconazole): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-2828
Measured over Predose and at designated timepoints up to approximately 288 hours (hrs) postdose
+3 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

History of cancer (malignancy)
History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases

What this trial measures

  • Part 1 (Itraconazole): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-2828Predose and at designated timepoints up to approximately 288 hours (hrs) postdose

    Blood samples will be collected at multiple time points to determine the AUC0-inf of MK-2828.

  • Part 1 (Itraconazole): Maximum Plasma Concentration (Cmax) of MK-2828Predose and at designated timepoints up to approximately 288 hrs postdose

    Blood samples will be collected at multiple time points to determine the Cmax of MK-2828.

  • Part 2 (Midazolam): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MidazolamPredose and at designated timepoints up to approximately 24hrs postdose

    Blood samples will be collected at multiple time points to determine the AUC0-inf of Midazolam.

  • Part 2 (Midazolam): Maximum Plasma Concentration (Cmax) of MidazolamPredose and at designated timepoints up to approximately 24hrs postdose

    Blood samples will be collected at multiple time points to determine the Cmax of Midazolam.